Summary of Global Pharmaceutical Licensing Agreements and Financing Events from September 16 to September 22.

RNA Interference (RNAi) is a gene-silencing mechanism first discovered in Caenorhabditis elegans, triggered by double-stranded small interfering RNA (siRNA).

Sep 20th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The development and application of siRNA drugs mark a revolution in the field of gene therapy, as they cleverly utilize the cellular RNA interference (RNAi) pathway to achieve precise regulation of disease-related gene expression.

Satellos Bioscience announced that the initial participant has received a dose in a Phase 1 clinical trial of SAT-3247.

Recently, Innovent Biologics announced promising clinical results for their potential first-in-class dual-specific antibody fusion protein targeting PD-1 and IL-2 (IBI363).

Fasenra granted approval in the United States for treatment of eosinophilic granulomatosis with polyangiitis.

Sep 19th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Givastomig is a pioneering first-in-class bispecific antibody immunostimulant targeting Claudin18.2 (CLDN18.2) and 4-1BB.

The FDA has greenlighted Novartis' Kisqali® to lower the chance of recurrence in patients with early-stage HR+/HER2- breast cancer.

Innovent Presents Clinical Results of IBI363 (Novel PD-1/IL-2α-bispecific Antibody) with Bevacizumab in Advanced Colorectal Cancer at 2024 ESMO Congress.

Senhwa Biosciences submits IND to FDA for NCI-sponsored Pidnarulex pharmacodynamics pilot study in advanced solid tumor patients.